Jazz Pharmaceuticals

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on developing innovative medicines for patients with serious diseases, particularly cancer and viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium, a potential treatment for acute myeloid leukemia, and brincidofovir, an antiviral candidate being developed as a medical countermeasure against smallpox. Chimerix's lead antiviral candidate, CMX001, is aimed at treating life-threatening double-stranded DNA viral diseases and has shown promising results in various clinical studies involving immunocompromised patients. Additionally, the company is developing CMX157, a nucleoside analogue with activity against HIV and hepatitis B, which has completed Phase 1 trials. Chimerix has established partnerships with organizations such as the Biomedical Advanced Research and Development Authority and SymBio Pharmaceuticals to further its research and commercialization efforts. The company generates revenue through license agreements, including upfront fees, royalties, and milestone payments.

Onera Health, Inc. specializes in providing innovative sleep diagnostic solutions and services aimed at identifying sleep disorders such as insomnia, sleep apnea, and narcolepsy. Founded in 2017 and headquartered in Palo Alto, California, with a research and development office in Eindhoven, the Netherlands, Onera Health has developed advanced sleep diagnostic patch systems that collect and analyze sleep data. These systems not only enhance the diagnosis of sleep-related ailments but also have potential applications in monitoring various chronic health conditions. By delivering comprehensive sleep test data to healthcare providers, Onera Health aims to improve patient care and reduce healthcare costs, ultimately enhancing the health and quality of life for individuals globally.

GW Pharmaceuticals is a biopharmaceutical company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of innovative therapeutics derived from its proprietary cannabinoid platform. Its primary product, Epidiolex, is an oral solution used to treat seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients aged one year and older, and it is also under review for the treatment of tuberous sclerosis complex. In Europe, the product is marketed as Epidyolex. The company also offers Sativex, which is used for managing spasticity due to multiple sclerosis, and is advancing various cannabinoid product candidates aimed at treating conditions such as schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. GW Pharmaceuticals operates primarily in Europe, the United Kingdom, and the United States, and has been established since 1998.

Cavion is a clinical stage pharmaceutical company committed to providing patients with therapies for cancer and neurologic diseases through the development of drugs that selectively inhibit the T-type calcium channel (Cav3). Built on the discovery by Cavion’s founders that ion channels are a target for the treatment of solid tumor cancers, they were the first company to invent therapies engaging Cav3 for the treatment of solid tumors. The innovative idea of treating pathologically proliferating, non-electrically excitable cells by targeting an ion channel has already shown success in preclinical studies and is being tested in Phase 1 safety and dose-finding clinical trials in brain cancer. Their technology is intended to magnify the effects of combined chemotherapy, radiation, and targeted therapies for all solid tumor cancers. Their neurology program uses superior chemistry and clinical expertise to deliver a novel class of drugs that will provide patients with treatments for neurologic diseases. While Cav3 is an established target in neurology, particularly neuropathic pain, Cavion is working to bring the first non-addictive, non-opioid T-type calcium channel antagonist to patients with neuropathic pain. Given that Cav3 plays a role in numerous pathologic conditions, Cavion is simultaneously developing therapies for additional neurologic afflictions such as essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome.

Onera Health, Inc. specializes in providing innovative sleep diagnostic solutions and services aimed at identifying sleep disorders such as insomnia, sleep apnea, and narcolepsy. Founded in 2017 and headquartered in Palo Alto, California, with a research and development office in Eindhoven, the Netherlands, Onera Health has developed advanced sleep diagnostic patch systems that collect and analyze sleep data. These systems not only enhance the diagnosis of sleep-related ailments but also have potential applications in monitoring various chronic health conditions. By delivering comprehensive sleep test data to healthcare providers, Onera Health aims to improve patient care and reduce healthcare costs, ultimately enhancing the health and quality of life for individuals globally.

Celator Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company specializes in creating optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Celator's product pipeline includes VYXEOS, a liposomal formulation of irinotecan and floxuridine, currently undergoing Phase III clinical trials for acute myeloid leukemia (AML). Additionally, CPX-351, another liposomal formulation of cytarabine and daunorubicin, is also in Phase III studies for AML. CPX-1, a combination of irinotecan and floxuridine, has completed Phase II trials targeting colorectal cancer. The company also has a preclinical candidate, CPX-8, which is a nanoparticle formulation of docetaxel. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Arrivo BioVentures LLC is a biopharmaceutical company based in Morrisville, North Carolina, established in 2015. The company specializes in the development of biologics and small molecules aimed at enhancing patient care. Arrivo BioVentures focuses on reformulating existing drugs and creating new chemical entities, employing its expertise to navigate regulatory strategies that streamline the approval process. By collaborating closely with regulatory bodies such as the FDA, the company aims to minimize unexpected challenges and accelerate the implementation of its clinical programs. Through its innovative approach, Arrivo BioVentures seeks to meet the demands of the biotechnology sector while prioritizing the improvement of patient outcomes.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Gentium S.p.A. is biopharmaceutical company specializing in the discovery, research, development and manufacture of active ingredients derived from natural sources as potential therapeutic agents. Gentium operates independently as a research facility and production plant for drug substance pharmaceuticals in Villa Guardia, near Como, Italy.

Azur Pharma is a privately held pharmaceutical company focused on improving patients' lives through the development and marketing of specialized therapeutic products. The company aims to address unmet medical needs by identifying, developing, and commercializing meaningful biopharmaceuticals. Its portfolio includes treatments for conditions such as cataplexy, excessive daytime sleepiness, acute lymphoblastic leukemia, and severe hepatic veno-occlusive disease. Azur Pharma's strategy involves evaluating and selectively acquiring late-stage development and approved pharmaceutical products, enhancing their value to better serve patients.

Orphan Medical is a healthcare company focused on developing specialty pharmaceuticals aimed at treating sleep disorders, pain, and other central nervous system conditions. By concentrating on these specific areas, the company seeks to address unmet medical needs and improve patient outcomes through innovative drug therapies.